Israeli medtech startup CustoMED has closed a $6 million funding round aimed at scaling its AI-driven, 3D-printed solutions for patient-specific orthopedic surgery. The round brought together strategic investors including Longevity Venture Partners, Varana Capital, Flag Capital, the Israel Innovation Authority, a leading orthopedic implant company, and Avishai Abrahami, co-founder and CEO of Wix.
CustoMED’s platform transforms conventional surgical planning. Using AI and automation, surgeons can convert pre-operative imaging into custom surgical guides and implants within minutes, rather than waiting weeks. These devices, produced onsite or via certified partners, integrate seamlessly into existing workflows, promising fewer intraoperative errors and more predictable outcomes. The technology has already been used in hundreds of surgeries worldwide, with thousands more scheduled for the coming year.
“CustoMED’s patient-specific surgical tools enable more precise orthopedic surgeries through affordable, real-time solutions delivered directly into the operating room,” said Or Benifla, co-founder of CustoMED. “By putting scalable, personalized technology directly in surgeons’ hands, our mission is to make computer-guided surgery routine, transforming what was once a boutique process into standard of care for every patient.”
Founded by Dr. Amit Zabatani, Or Benifla, and Alon Jacobi, CustoMED emerged from Sheba Medical Center’s 3D Printing & Innovation Lab. The lab, originally established in 2018 by Dr. Dina Orkin with the co-founders, has embedded 3D-printed technologies into routine patient care across multiple hospital departments. CustoMED operates within Sheba’s ARC Innovation ecosystem, which accelerates clinician-led innovations globally.
“CustoMED is embedding precision and surgeon-directed tools into everyday workflows, shortening the path from imaging to the operating room while preserving governance, quality, and safety,” said Prof. Eyal Zimlichman, founder and director of ARC Innovation and Chief Innovation, Transformation, and AI Officer at Sheba Medical Center.
The fresh capital will fuel the company’s expansion into additional orthopedic indications, support U.S. and EU regulatory milestones expected in 2026, and scale its on-demand manufacturing model globally. Raissa Hacohen, Managing Partner at Longevity Venture Partners, emphasized the platform’s potential: “CustoMED gives surgeons everywhere access to personalized planning and surgical tools that can raise the standard of care in orthopedic surgery.”
Editorial Perspective:
CustoMED exemplifies a shift in medtech where AI and 3D printing intersect with surgeon autonomy, moving from pre-fabricated implants to bespoke, patient-specific solutions. By streamlining production from imaging to the OR, it addresses a long-standing bottleneck in orthopedic care—precision at scale.
The company’s integration within Sheba Medical Center’s ARC Innovation ecosystem provides both clinical credibility and a pathway to global adoption. As regulatory approvals in the U.S. and EU approach, the startup could emerge as a benchmark for surgeon-driven AI platforms in orthopedics. Investors backing CustoMED are essentially betting on a future where personalized, real-time surgical solutions become the baseline rather than the exception.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com. For more such articles visit www.thetimesmag.com
